{"name": "Yaupon Therapeutics",
 "permalink": "yaupon-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/yaupon-therapeutics",
 "homepage_url": "http://www.yaupontherapeutics.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "610-975-9290 ",
 "description": "",
 "created_at": "Fri Aug 12 02:24:55 UTC 2011",
 "updated_at": "Fri Aug 12 02:24:54 UTC 2011",
 "overview": "\u003Cp\u003EYaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). If approved, Yaupon\u00e2\u20ac\u2122s investigational drug would be the first topical mechlorethamine gel widely available to treat the signs and symptoms of this rare cancer. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       66],
      "assets/images/resized/0014/9091/149091v1-max-150x150.png"],
     [[210,
       93],
      "assets/images/resized/0014/9091/149091v1-max-250x250.png"],
     [[210,
       93],
      "assets/images/resized/0014/9091/149091v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman and CEO",
    "person":
     {"first_name": "Stephen",
      "last_name": "Tullman",
      "permalink": "stephen-tullman-2",
      "image": null}},
   {"is_past": false,
    "title": "CFO \u0026 COO",
    "person":
     {"first_name": "Doug",
      "last_name": "Gessl",
      "permalink": "doug-gessl",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$14.4M",
 "funding_rounds":
  [{"round_code": "d",
    "source_url": "http://www.finsmes.com/2011/08/yaupon-therapeutics-raises-14-4m-series-funding.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Yaupon Therapeutics Raises $14.4M in Series D Funding",
    "raised_amount": 14400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 8,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Vivo Ventures",
         "permalink": "vivo-ventures",
         "image":
          {"available_sizes":
            [[[150,
               62],
              "assets/images/resized/0004/6854/46854v1-max-150x150.png"],
             [[200,
               83],
              "assets/images/resized/0004/6854/46854v1-max-250x250.png"],
             [[200,
               83],
              "assets/images/resized/0004/6854/46854v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Palo Alto Investors",
         "permalink": "palo-alto-investors",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0001/9366/19366v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0001/9366/19366v2-max-250x250.png"],
             [[288,
               42],
              "assets/images/resized/0001/9366/19366v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Burrill \u0026 Company",
         "permalink": "burrill-co",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0402/50402v1-max-150x150.png"],
             [[250,
               43],
              "assets/images/resized/0005/0402/50402v1-max-250x250.png"],
             [[250,
               43],
              "assets/images/resized/0005/0402/50402v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Aperture Venture Partners",
         "permalink": "aperture-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               46],
              "assets/images/resized/0006/2293/62293v1-max-150x150.jpg"],
             [[208,
               65],
              "assets/images/resized/0006/2293/62293v1-max-250x250.jpg"],
             [[208,
               65],
              "assets/images/resized/0006/2293/62293v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "101 Lindenwood Drive",
    "address2": "Suite 400 ",
    "zip_code": "19355 ",
    "city": "Malvern",
    "state_code": "PA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}